JPMorgan trims AbbVie target, removes from Analyst Focus List
JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Business Insider15h
AbbVie Hold Rating Maintained Amid Emraclidine Trial Challenges and Competitive Pressure
These factors collectively influenced David Risinger to maintain a Hold rating for AbbVie, reflecting a cautious stance while the company continues to analyze the trial data to determine future steps.
World Pneumonia Day: Staying protected with immunizations and healthy habits
Some ways to protect yourself from pneumonia are: Make sure you’re up to date on your immunizations. Practice good health ...
BBC14h
Market Data
© 2024 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking.
BBC13h
Market Data
From the end of November Market data will no longer be displayed here. As of 3:25 13 Nov 2024 15 min delay Source: Morningstar © 2024 BBC. The BBC is not responsible ...